US based cardiac technology company HeartBeam has been awarded a third US patent for its 12-lead extended wear patch.
The latest patent was granted by the United States Patent and Trademark Office, bringing the company’s total number of patents to 15, with 11 of them being US- based and four of them internationally based. They also have 18 pending patent applications in the works.
Portable and compact, HeartBeam’s device is the size of a credit card and is centred around the company’s 3D-vector electrocardiogram (VECG) platform. The platform remains in constant proximity to the patient, allowing for the generation of comprehensive data for artificial intelligence (AI) applications.
Commenting on the latest development, HeartBeam CEO, Branislav Vajdic, said: “We believe our 12-lead electrocardiogram (ECG) technology has the potential to become the standard of care and are actively pursuing options to bring the 12-lead extended wear patch to market.”
The global diagnostic ECG device market, excluding supplies, is approximately $7.5 billion per year according to a GlobalData report. By 2024 that value is predicted to increase to $10.3 billion at a compounded annual growth rate (CAGR) of 6.4%. Currently the US accounts for 25% of the global ECG market.
In August 2023 HeartBeam published a study (Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration) which demonstrated the capability of its VECG platform to detect coronary artery blockages. The study indicated that the automated analysis of the VECG and 12L ECG signals had similar performance in determining whether the artery was occluded. Also in the study, the human interpretation of the 12L ECGs had significant intra-and inter-observer variability, which does not occur with automated readings.
